Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HBM-7008 by Harbour BioMed (Guangzhou) for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
HBM-7008 is under clinical development by Harbour BioMed (Guangzhou) and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...